secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001628280-24-026295
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology rescinds 1.7M options, regrants same subject to stockholder approval
--------------------------------------------------------------------------------

- Board rescinded 1,697,712 options granted on March 7, 2024 at $3.51/share.
- Board regranted 1,697,712 options at same $3.51 strike, contingent on June 20, 2024 stockholder vote.
- Stockholder approval required to increase shares available under 2021 Equity Incentive Plan.
- Bylaw amended to align voting standards: plurality for directors, majority for other matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024026295/0001628280-24-026295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024026295/crdf-20240530.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-026295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer